Artificial intelligence for pancreatic cancer: PANCAIM celebrates 1-year anniversary

Pancreatic cancer is responsible for over 95,000 EU deaths every year, and the average life expectancy at the time of diagnosis is just 4.6 months, making it one of the most deadly types of cancer.

Motivated by the idea of helping patients and improving their quality of life, as well as completing and consolidating the currently rather scattered research in the field, the PANCAIM project is centered around the consortium’s proposal to build a repository of available multi-modal patient data. Combining manual and automatic annotation and analysis of features from genomics, and medical imaging (radiology, pathology), this data will be used for machine learning and AI training. The developed algorithms will help clinicians to make a more accurate prognosis and offer better treatment recommendations and outcome predictions for patients with pancreatic cancer. This will increase thus survivability and quality of life of those affected.

At the project’s M12 meeting, which took place on Friday, 14th January 2022 online, the Consortium celebrated successfully completing the first 12 months of project implementation and reaching the 1-year milestone of PANCAIM. Partners presented their progress in their research and cooperation efforts and explained plans for the upcoming months. The project’s External Advisory Board (EAB) members shared valuable feedback and constructive feedback that will be taken into account during the remaining 3 years of the project. After a successful and insightful exchange on the sustainability of the project during the General Assembly meeting, PANCAIM partners are more inspired than ever to continue their work on the project in 2022 and reach the desired impacts. 

To learn more about the project, please visit https://pancaim.eu/.